^
    Apply
    A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients (NCT05787613)
    Phase 2
    Shanghai Henlius Biotech
    Recruiting
    Last update posted :
    02/22/2024
    Initiation :
    07/10/2023
    Primary completion :
    07/01/2025
    Completion :
    07/01/2027
    PD-L1 • ROS1 • LAG3
    |
    PD-L1 expression • ROS1 rearrangement • LAG3 expression
    |
    carboplatin • albumin-bound paclitaxel • pemetrexed • Hetronifly (serplulimab) • HLX26
    Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of HLX26 and HLX10 in Patients With Advanced/Metastatic Solid Tumor (NCT05400265)
    Phase 1
    Shanghai Henlius Biotech
    Completed
    Last update posted :
    02/06/2024
    Initiation :
    07/26/2022
    Primary completion :
    08/31/2023
    Completion :
    01/31/2024
    ROS1
    |
    Hetronifly (serplulimab) • HLX26
    Evaluate the Efficacy, Safety and Tolerability of HLX26 and Serplulimab in Patients With mCRC (NCT05584137)
    Phase 2
    Shanghai Henlius Biotech
    Suspended
    Last update posted :
    08/11/2023
    Initiation :
    06/15/2023
    Primary completion :
    08/30/2024
    Completion :
    04/30/2026
    KRAS • BRAF
    |
    BRAF mutation • KRAS wild-type • RAS wild-type
    |
    Hetronifly (serplulimab) • HLX26